Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
They will commercialize molnupiravir in the international markets
This is the company’s first partnership arrangement in China
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
It provides Covid-19 detection and Omicron surveillance in less than two hours
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Narayanan to lead SeQuent through next phase of consolidation and growth
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Subscribe To Our Newsletter & Stay Updated